Factorial Partners LLC Reduces Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Key Points

• Factorial Partners LLC reduced its stake in AngioDynamics by 31%, bringing its ownership to 78,000 shares valued at $732,000 as of the latest SEC filing.
• Several institutional investors, including MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. and Price T Rowe Associates Inc., have increased their stakes in AngioDynamics, indicating a continued interest in the company.
• AngioDynamics reported an earnings beat with a net revenue of $80.16 million for the last quarter, surpassing estimates and showing a growth of 13% year-over-year.

Factorial Partners LLC lessened its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 31.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 78,000 shares of the medical instruments supplier's stock after selling 35,000 shares during the quarter. Factorial Partners LLC owned about 0.19% of AngioDynamics worth $732,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Quinn Opportunity Partners LLC purchased a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $92,000. ProShare Advisors LLC purchased a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $100,000. Graham Capital Management L.P. purchased a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $106,000. OneDigital Investment Advisors LLC grew its holdings in shares of AngioDynamics by 14.0% during the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock valued at $111,000 after buying an additional 1,490 shares during the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of AngioDynamics by 22.0% during the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 2,333 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

Analysts Set New Price Targets

ANGO has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 16th. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Lake Street Capital started coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective on the stock.

AngioDynamics Stock Down 0.2%

ANGO traded down $0.02 during trading on Friday, hitting $8.51. The company's stock had a trading volume of 719,168 shares, compared to its average volume of 809,494. AngioDynamics, Inc. has a one year low of $5.83 and a one year high of $13.50. The firm has a market cap of $345.76 million, a PE ratio of -10.25 and a beta of 0.67. The business's 50 day simple moving average is $9.64 and its 200-day simple moving average is $9.81.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.09. The firm had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company's revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm earned ($0.06) EPS. Equities research analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.